• Ulrich Schwabe
  • Reinhard Ziegler


Grundlage der Behandlung der Osteoporose sind (neben Schmerzmitteln) nichtmedikamentöse Maßnahmen und eine ausreichende Zufuhr von Calcium und Vitamin D als Basistherapie (Rizzoli et al. 2008). Die spezifische Osteoporosetherapie stützt sich auf den Einsatz der knochenabbauhemmenden Antiresorptiva (Bisphosphonate, Raloxifen, Denosumab) und der knochenaufbaufördernden Osteoanabolika (Strontiumranelat, Teriparatid, Parathormon) (Übersicht bei Rachner et al. 2011).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia, pp. 827-839, 885-902.Google Scholar
  2. Arzneimittelkommission der Deutschen Ärzteschaft (2008): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet:
  3. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, Heaney R, Seeman E, Papapoulos S, Goldring SR (2009): Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR Workshop. J Bone Miner Res 24: 373-385.Google Scholar
  4. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving he- modialysis. N Engl J Med 350: 1516-1525.PubMedCrossRefGoogle Scholar
  5. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441.PubMedCrossRefGoogle Scholar
  6. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010): Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341: c3691.CrossRefGoogle Scholar
  7. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez- Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004): Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.PubMedCrossRefGoogle Scholar
  8. Brancaccio D, Cozzolino M (2007): Lanthanum carbonate: time to abandon prejudices? Kidney Int 71: 190-192.PubMedCrossRefGoogle Scholar
  9. Brown JE, Coleman RE (2012): Denosumab in patients with cancer-a surgical strike 37 against the osteoclast. Nat Rev Clin Oncol 9: 110-118.PubMedCrossRefGoogle Scholar
  10. Compston J (2009): Recent advances in the management of osteoporosis. Clin Med 9: 565-569.PubMedGoogle Scholar
  11. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009): Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756-765.PubMedCrossRefGoogle Scholar
  12. Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillön JL, Perez- Cano R, Munoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonzalez-Macias J (2012): Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27: 817-824.PubMedCrossRefGoogle Scholar
  13. Drüeke TB (2007): Lanthanum carbonate as a first-line phosphate binder: the „cons". Semin Dial 20: 329-332.PubMedCrossRefGoogle Scholar
  14. Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S (2011): Safety and efficacy of the cathepsin K inhibitor ONO-5334 in post- menopausal osteoporosis: the OCEAN study. J Bone Miner Res 26: 1303-1312.PubMedCrossRefGoogle Scholar
  15. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA (2008): Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 23: 112-120.PubMedCrossRefGoogle Scholar
  16. Favia G, Pilolli GP, Maiorano E (2009): Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406-413.PubMedCrossRefGoogle Scholar
  17. Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47-53.PubMedCrossRefGoogle Scholar
  18. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women's Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669-683.PubMedCrossRefGoogle Scholar
  19. Keaveny TM, Donley DW, Hoffmann PF et al. (2007): Effects of teriporatide and alend- ronate on vertebral strength as assessed by finite element modeling of QCT scars in women with osteoporosis. J Bone Miner Res 21: 149-157.Google Scholar
  20. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JP, Pieger CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007): Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1810.PubMedCrossRefGoogle Scholar
  21. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878.PubMedCrossRefGoogle Scholar
  22. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459-486.PubMedCrossRefGoogle Scholar
  23. Mousny M, Bouse X, Wise L, Everett ET, Hancock R, Vieth R, Devogelaer JP, Grynpas MD (2006): The genetic influence on bone susceptibility to fluoride. Bone 39: 1283-1289.PubMedCrossRefGoogle Scholar
  24. NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942-1948.CrossRefGoogle Scholar
  25. Pazianas M, Compston J, Huang CL (2010): Atrial fibrillation and bisphosphonate thera- py. J Bone Miner Res 25: 2-10.PubMedCrossRefGoogle Scholar
  26. Rachner TD, Khosla S, Hofbauer LC (2011): Osteoporosis: now and the future. Lancet 377: 1276-1287.PubMedCrossRefGoogle Scholar
  27. Reginster JY, Bruyere O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP (2009): Long-term treatment of postmenopausal osteoporosis with strontium ra- nelate: results at 8 years. Bone 45: 1059-1064.PubMedCrossRefGoogle Scholar
  28. Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008): The role of calcium and vitamin D in the management of osteoporosis. Bone 42: 246-249.PubMedCrossRefGoogle Scholar
  29. Sainz M, del Pozo JG, Arias LH, Carvajal A (2009): Strontium ranelate may cause alopecia. BMJ 338: 1494-1498.CrossRefGoogle Scholar
  30. Schousboe JT, Nyman JA, Kane RL, Eusrud KE (2005): Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142: 734-741.PubMedGoogle Scholar
  31. Seeman E, Devogelaer J-P, Lorenc R, Spector T, Brixeu K, Balogh A, Stucki G, Reginster JY (2008): Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23: 433-438.PubMedCrossRefGoogle Scholar
  32. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research (2010): Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267-2294.PubMedCrossRefGoogle Scholar
  33. Silverberg SJ, Fairman C, Bilezikian JP et al. (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103.Google Scholar
  34. Suki W, Zabaneh R, CangianoJ, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the im- pact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21 (Suppl 4): 145-146.Google Scholar
  35. Tashjian AH Jr, Goltzman D (2008): On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J Bone Miner Res 23: 803-811.PubMedCrossRefGoogle Scholar
  36. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012): Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50: 870-875.PubMedCrossRefGoogle Scholar
  37. Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570-577.Google Scholar

Copyright information

© Springer Medizin Verlag Berlin, Heidelberg 2012

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  • Reinhard Ziegler
    • 2
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg
  2. 2.Heidelberg

Personalised recommendations